Mounjaro®
Starting from £179.99/mo
Start journey Learn moreNo, you are not required to stay on Wegovy forever — but stopping it usually means some or all of the weight you lost returns, because the medicine addresses an ongoing biological driver rather than fixing it permanently. Most clinical evidence, including the STEP 1 trial published in the New England Journal of Medicine, shows that weight tends to come back after treatment ends. How long you stay on it is a conversation to have with your prescriber, not a rule set in advance.
At your door the next working day.
Free, tracked, plain packaging.
BMI isn't the whole story, but it's where clinicians start. Check yours in ten seconds — nothing is stored, nothing is shared.
Ten seconds. Private — nothing is stored or shared.
Your result updates live in the card alongside.
Your result
Your BMI is
—
which is in the healthy weight range
Start journeyBMI doesn't determine eligibility — only a clinician can assess whether treatment is right for you.
The problem
The nume way
clinician review. Free next working day delivery.
How it works
Tell us about your health, history and goals. Free, online, and confidential — no commitment, no waiting room.
Our team reviews your health the same day — never an algorithm, and approves your treatment there and then if eligible.
Order by 12pm, dispatched same day, delivered free the next working day — the nume Promise.
A lot of people start Wegovy expecting that once they reach their target weight, the medicine has done its job and they can simply move on. That is a reasonable expectation but the biology does not quite work that way.
Semaglutide, the active ingredient in Wegovy, reduces appetite by acting on GLP-1 receptors in the brain and gut. The medicine does not alter the underlying tendency of the body to return to a higher weight set-point; it manages it. Stopping the injection means the appetite signals that drove weight gain in the first place gradually reassert themselves. In the STEP 1 trial, participants who stopped semaglutide after 68 weeks regained, on average, around two-thirds of the weight they had lost within a further year, even when they continued a behavioural programme. That figure is uncomfortable, but it is important to know it going in.
This does not mean treatment must last forever. It does mean the question "how long should I take this?" deserves a proper clinical answer rather than an assumption.
On the NHS, NICE guidance on semaglutide (TA875) recommends it for a maximum of two years, within a specialist weight management service that includes dietetic and behavioural support. The two-year cap reflects both the trial duration and NHS resource considerations; it is not a statement that two years is always enough or that private treatment should follow the same ceiling.
If you are asking whether you have to take Wegovy long-term, the honest answer is: it depends on your health goals, your response to treatment, and what your prescriber thinks is appropriate for you. Some people choose to continue beyond two years privately; some plateau, reassess, and stop with a structured plan in place. Neither path is automatically right.
It is also worth knowing that the NHS England guidance on weight management injections is explicit that treatment should sit alongside diet, activity and behavioural support, not replace them. Building those habits during treatment is what gives stopping a better chance of going well.
If you and your prescriber decide to stop, the process and the timeline matter. Abrupt stopping after a prolonged course can trigger a rapid return of appetite. Some people taper; some stop from maintenance dose; the right approach depends on your dose, how long you have been taking it, and your circumstances. That is a conversation for your prescriber, not a decision to make based on what you read online.
Practically, the period after stopping is when routine matters most. Many people find that the habits built during treatment (the protein-forward meals, the regular activity, keeping the pen in the fridge door as a daily reminder of the programme) become the structure that slows the rebound. They are not a substitute for the medicine, but they are far more useful than nothing.
If cost is a factor in your thinking about how long you have to stay on Wegovy, our Wegovy pricing page explains exactly what a private prescription includes and how the cost breaks down. At nume, every repeat order goes through a fresh clinical review, there are no subscriptions and nothing auto-renews, so the question of whether to continue is revisited properly each time, not decided once and forgotten.
Some people do stop and maintain their lower weight, particularly those who have built strong metabolic and lifestyle foundations during treatment, or who have lost weight that was driven by a specific, now-resolved factor. They are a minority in the trial data, but they exist. Whether long-term continuation or a planned stop is the better approach for you is exactly the kind of question our prescribers work through at each review.
What is clear from the evidence is that the decision should be active, not passive. If you are wondering whether you need to stay on Wegovy forever, drifting off treatment because of cost, side effects or inconvenience without a plan tends to produce worse outcomes than a deliberate, supported transition. If you are weighing your options, speaking to a prescriber is the right starting point. You can check your eligibility and start a free consultation to have that conversation properly.
The people
Superintendent Pharmacist (GPhC No. 2217101)
Accountable for the safe running of our registered pharmacy, from every dispensing check to every dispatch.
Clinical Lead (GPhC No. 2231744)
Sets our clinical standards and checks everything we publish against current MHRA guidance.
Independent Prescriber (GPhC No. 2084501)
Personally reviews consultations and assesses whether treatment is clinically appropriate, and leads dose adjustments and follow-up checks.
Independent Prescriber (GPhC No. 2083426)
Personally reviews consultations and assesses whether treatment is clinically appropriate, and leads dose adjustments and follow-up checks.